Decision to list Interventional Radiology products supplied by Defries Industries New Zealand and Abbott Laboratories NZ Limited
15 June 2018
What we are doing
We’re pleased to announce the approval of a listing agreement for Interventional Radiology products with Abbott NZ Limited (“Abbott”) and Defries Industries New Zealand (“Defries”).
In summary this will result in:
- 773 Interventional Radiology products from Abbott being listed in Part III of Section H of the Pharmaceutical Schedule from 1 July 2018.
- 10 Interventional Radiology products from Defries being listed in Part III of Section H of the Pharmaceutical Schedule from 1 July 2018.
- National savings estimated at $13,000 per annum on the purchase of Abbott’s Interventional Radiology products, assuming no change to current usage levels or product mix.
- No additional expenditure on the purchase of Defries’ Interventional Radiology products, assuming no change to current usage levels or product mix.
This Agreement would supersede any existing DHB contracts with this supplier for the devices listed in Schedule One of the Agreement.The list of Abbott and Defries Interventional Radiology products will be available on PHARMAC's website from 1 July 2018, in both a PDF document and an Excel spreadsheet.
Any changes to the original proposal?
No changes were made to the listing agreement as a result of consultation feedback.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff:
- Interventional radiology clinical staff
- Procurement Officers
Detail about this decision
In September 2017 PHARMAC issued a request for proposals (“RFP”) for Interventional Radiology Products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation, and consulting on the provisional agreements reached with Abbott and Defries, PHARMAC has decided to list both Abbott’s and Defries’ range of Interventional Radiology Products in Part III of Section H of the Pharmaceutical Schedule from 1 July 2018.
DHBs that purchase Abbott’s or Defries’ Interventional Radiology Products must do so under the terms and conditions, and at the prices, included in the Agreements, from 1 July 2018.
DHBs can continue to choose which Interventional Radiology products they purchase.
Abbott’s and Defries’ products are the most recent Interventional Radiology products that PHARMAC has decided to list on the Pharmaceutical Schedule. Further consultations in this category are expected over the next few months.
Our response to what you told us
We’re really grateful for the time people took to respond to this consultation. A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
PHARMAC Staff Comment
Queried the time allowed for consultation noting it is shorter than PHARMAC typically allows.
PHARMAC responded that as in the consultation letter the last date for consultation was the 18th of May.
PHARMAC noted that the time allowed for consultation was considered appropriate due to the low impact of national contracting.
Advising that no technical or resource impacts are anticipated as a result of Device Technologies proposal.
If you have any questions about this decision, you can email us at firstname.lastname@example.org; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 16 July 2020